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a  b  s  t  r  a  c  t
The  World  Health  Organization  (WHO)  vaccines  prequaliﬁcation  programme  was  established  in  1987.
It  is  a service  provided  to United  Nations  procurement  agencies  to ensure  that  the  vaccines  supplied
through  these  agencies  are  consistently  safe and  effective  under  conditions  of use  in national  immuniza-
tion  programmes.  This  review  describes  the  purpose  and  aims  of  the  programme,  its  evolution  during  25
years of existence,  its  added  value,  and its role  in  the context  of the  WHO  strategy  to  ensure  the  globaleywords:
accine prequaliﬁcation programme
ational immunization programme
lobal public health
accines of assured quality
availability  of  vaccines  of  assured  quality.  The  rationale  for  changes  introduced  during  the  implemen-
tation  of  the  programme  is provided.  The  paper  also  discusses  the  resources  involved,  both  human  and
ﬁnancial,  its  performance,  strengths  and  weaknesses  and  steps  taken to  maximize  its  efﬁciency.  This
historical  perspective  is  used  to inform  proposed  future  changes  to the  service.
©  2013  World  Health  Organization.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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. Introduction
WHO  prequaliﬁcation aims to ensure that selected diagnostics,
edicines, vaccines, immunization-related equipment and devices
or high burden diseases meet global standards of quality, safety
nd efﬁcacy, in order to optimize use of health resources and
mprove health outcomes. It consists of a transparent and scien-
iﬁcally sound assessment process that in conjunction with other
rocurement criteria is used by United Nations (UN) and other
rocurement agencies to make purchasing decisions regarding
peciﬁc commodities (diagnostics, medicines and/or vaccines).
requaliﬁcation (PQ) is a procurement term [1] which refers to
imiting a global public tender to fewer than the total number of
ossible suppliers.
The vaccines prequaliﬁcation programme was  established in
987. It was conceived as a service provided by the WHO  to the
upply Division of its sister agency the United Nations Children’s
und (UNICEF). Its primary purpose was to ensure that the vac-
ines purchased by UNICEF and other UN procurement agencies
ould be consistently safe and effective under conditions of use in
ational immunization programmes. It started as a modest project,
ased on the testing of vaccine lots; review of summary lot pro-
ocols and also on inspection of the manufacturing facilities. As
emand increased and needs evolved, the procedure was revised to
trengthen its capacity to assess quality, safety and efﬁcacy of the
andidate vaccines for purchase through the UN agencies. The revi-
ions of the procedure were triggered by changing needs and were
ntroduced in the majority of cases based on recommendations by
roups of experts (the ad hoc committee on vaccines prequaliﬁca-
ion). Every revision was further either endorsed or noted by the
HO Expert Committee on Biological Standardization (ECBS) prior
o its implementation and publication as part of the WHO  Technical
eport Series (TRS) or as a Vaccines Department document.
. The problem
The WHO  Constitution was adopted by the International Health
onference held in New York from 19 June to 22 July 1946,
igned on 22 July 1946 by the representatives of 61 States [2]
nd entered into force on 7 April 1948. Amendments adopted by
he Twenty-sixth, Twenty-ninth, Thirty-ninth and Fifty-ﬁrst World
ealth Assemblies (resolutions WHA26.37, WHA29.38, WHA39.6
nd WHA51.23) came into force on 3 February 1977, 20 January
984, 11 July 1994 and 15 September 2005 respectively. Those
mendments are incorporated in the present text [3].
According to the article 2 of the Constitution, WHO’s mandate
s to “develop, establish and promote international standards with
espect to food, biological, pharmaceutical and similar products”.
HO  Member States rely on WHO  for expertise and guidance in
he regulation, safety and quality assurance of medicines through
evelopment and promotion of international norms, standards,
uidelines and nomenclature.
In view of this mandate expert committees were established to
evelop and promote appropriate quality standards in the areas
f pharmaceutical and biological products, including vaccines. The
CBS was established and has met  annually since 1947 [4] and is
esponsible for assisting the WHO  secretariat in the development
nd establishment of written and physical standards for biological
roducts.
One of the challenges faced by WHO  in the ﬁeld of biological
roducts was to ensure that vaccines used both domestically and
lobally would meet the appropriate standards of quality, safety
nd efﬁcacy. This was an issue of particular concern taking into
ccount the speciﬁc characteristics of vaccines which are used
ostly as preventive medicines in healthy populations and in many
ases in newborns and healthy infants.cine 33 (2015) 52–61 53
After the Expanded Programme for Immunization (EPI) was
started in 1974, vaccines were supplied either by multinational
manufacturers or national vaccine producers. Increasingly, prod-
ucts were bought by UN procurement agencies – UNICEF and the
Pan American Health Organization Revolving Fund (PAHO RF) [5]
[6].
These agencies were conscious of the need to ensure the quality,
safety and efﬁcacy of the products they procured and distributed.
The following was noted in an EPI Newsletter [7].
“PAHO/WHO screen manufacturers offering vaccines for EPI use
and, where possible, review protocols of the speciﬁc lots submitted
for sale.”
Much emphasis was  initially placed on the national testing of
vaccines or the use of WHO  or PAHO testing centres [8]. At its
84th meeting in June 1980, the PAHO Executive Committee urged
all Member States to strengthen their respective laboratories for
vaccine testing [9].
In 1987, UNICEF established an agreement with WHO  to request
its involvement in assessing the acceptability, in principle, of vac-
cines for purchase through this agency. Through this agreement,
WHO supported UNICEF by providing advice on the quality, safety
and efﬁcacy of vaccine candidates for purchase.
3. The prequaliﬁcation procedure: early days
Based on this request, WHO  published in 1987 its ﬁrst set of
requirements for prequaliﬁcation [10], supplemented the following
year by a modiﬁcation applicable exclusively to BCG vaccine [11],
because of the requirement as published in the TRS for annual clin-
ical trials to establish the consistency of production of this vaccine.
The early process focused on review of consistency of production
(generally by review of summary lot protocols and by testing, but
supplemented with clinical trials for BCG), and an inspection to
the manufacturing site(s). In some cases a small ﬁle was provided
by manufacturers to give information about the production pro-
cess, strain development and involvement of NCA and NCL in the
oversight of the product.
This started to be known as the WHO  prequaliﬁcation proce-
dure. Through this evaluation process, WHO  limited the number
of suppliers of a speciﬁc vaccine to fewer than the total possible
candidates. This reduced population of suppliers of “prequaliﬁed
vaccines” was further subject to a ﬁnal “selection or qualiﬁcation”
that is carried out by UNICEF based on procurement principles and
using a tender process that ends up in granting an award.
The service provided by WHO  to UNICEF, eventually was
extended to the PAHO RF, and with time it became a standard
service provided to any UN procuring agency including WHO  Head-
quarters and all regional ofﬁces.
In addition to securing a standard quality for vaccines for global
supply, there was  a need to ensure regulatory systems at national
level had the infrastructure and capacity to oversee the quality,
safety and efﬁcacy of products used within their territories. This
was particularly important for countries with domestic produc-
tion of vaccines and for those procuring vaccines directly through
international bidding.
WHO’s ECBS published in 1981 its ﬁrst guideline on national
control of vaccines, recommending the establishment of a “national
control authority” (now called national regulatory authority) [12]
for all countries, with responsibilities that may  differ accord-
ing to their capacity and need. A national control authority was
recommended to be empowered to establish or recognize require-
ments for acceptability of products, establish standard preparations
for biological testing, license manufacturers of biological prod-
ucts, and establish the necessary infrastructure to implement the
54 N. Dellepiane, D. Wood / Vaccine 33 (2015) 52–61
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equirements. At this point, most of the emphasis was  placed on
he testing related activities.
The Forty-ﬁfth World Health Assembly in 1992 resolved that all
accines used in national immunization programmes should meet
HO  requirements (WHA45.17), thus reinforcing former guide-
ines as a credible goal for all countries.
. Strategic approach to strengthening national regulatory
apacity for vaccine regulation
WHO  has further reﬁned its guidance towards the development
nd strengthening national regulatory capacity by introducing and
eﬁning the key concept of “vaccines of known good quality”.
According to WHO, a vaccine is of known good quality [13]1
rovided that:
The national regulatory authority independently controls the
quality of the vaccine in accordance with the six speciﬁed func-
tions deﬁned by WHO, and
There are no unresolved conﬁrmed reports of quality-related
problems.
Implicitly, this requires that the NRA of the vaccine producing
ountry be functional when assessed against international stan-
ards for vaccine regulation.
Comprehensive regulatory oversight of vaccines requires a reg-
latory system and six basic functions [14,15]. These functions
re: (1) Marketing authorization and facility licensing; (2) Phar-
acovigilance including Adverse Events Following Immunization
AEFI); (3) NRA lot release; (4) Laboratory access; (5) Regulatory
nspections; and (6) Authorization and monitoring of clinical trials.
To support countries to build appropriate regulatory capacity
HO developed a strategy to prioritize capacity building on the
1 Since the publication of this document, WHO  has used the term “assured qual-
ty”  rather than “known good quality” and refers to National Regulatory Authorities
ather than National Control Authorities (NCAs).ritized by vaccine source [16].
NRA’s essential functions depending on the source of the vaccine
(Fig. 1) [16]. This allowed with limited resources to focus on the
most relevant functions. In this respect, countries purchasing
vaccines through UN agencies were recommended to perform only
two functions: marketing authorization and pharmacovigilance
including Adverse Events Following Immunization (AEFIs). The
other four functions are secured by the WHO  prequaliﬁcation
system which ensures continued regulatory oversight by the NRA
in the country of origin and compliance with WHO  requirements,
UN tender speciﬁcations and with the speciﬁc needs of national
immunization programmes in user countries.
Non-producing countries procuring vaccines directly through
international tenders are recommended to fulﬁl two additional
functions: lot release and laboratory access. This means that they
need to release each lot of vaccine to be used in the country through
critical review of the summary lot protocols provided by the man-
ufacturer with the shipment, and need to have access to a qualiﬁed
laboratory capable of testing the vaccine products in case of need.
There is no need to establish a laboratory in each vaccine procuring
country so that it can be accessed when needed. The remaining two
functions are secured by the NRA of country of origin.
The highest priority countries for capacity strengthening remain
the vaccine producing countries, some of which may be exporters
while others focus on the domestic supply of vaccines. These
countries should fulﬁl the six functions.
Based on this prioritization mechanism and with producing
countries as the highest priority, WHO  developed in 1995 a 5 step
capacity building programme to strengthen NRAs [16] that relies
on:
(1) Establishment of benchmarks to objectively and reliably assess
a national regulatory system for vaccines,
(2) A review, led by WHO, by a team of international experts to
conduct the assessment of a national regulatory system. The
assessment is performed by using an assessment tool with indi-
cators and sub-indicators for each regulatory function,
(3) Identiﬁcation of gaps and weakness, and development of an
Institutional Development Plan (IDP) to address the gaps,
 / Vac
(
(
4
o
[
i
s
r
d
T
o
t
F
g
q
i
p
a
5
c
1
n
p
t
•
•
•
l
s
m
t
t
i
a
c
w
c
m
e
g
e
cN. Dellepiane, D. Wood
4) Provision of technical input and support through learning and
training to build capacity in line with the needs identiﬁed
through the IDP, and
5) Monitoring progress and re-assessment of the performance of
the regulatory system at regular intervals.
.1. Development of a NRA assessment tool
The capacity building programme started in 1996 and was built
n existing regulatory authorities with expertise to regulate drugs
17,18]. The ﬁrst NRA assessment tool was developed in 1997 with
nputs from many countries (38 in the ﬁrst round) (J.B. Milstien per-
onal communication), and between 1997 and 2004 the tool was
evised 4 times. During the same period, 68 assessments were con-
ucted and 1200 staff trained [19,20]. At the same time, the Global
raining Network (GTN) was established by WHO  involving collab-
rating centres around the world that provided training courses
o bridge the gaps identiﬁed during the NRA assessment process.
urther revisions of the tool were conducted in 2007 and 2011.
Thus, WHO  established a dual and parallel system to secure the
lobal supply of vaccines of assured quality; on one hand the pre-
ualiﬁcation procedure ensured the quality of vaccines distributed
nternationally through UN agencies, while the capacity building
rogramme worked towards strengthening the regulatory capacity
t country level.
. The vaccines prequaliﬁcation programme: its evolution
After the initial publication of the vaccine prequaliﬁcation pro-
edure in 1987, this was further revised in 1988 and reissued in
989 [21]. This later edition took into account the need for the
ational regulatory authority of the country where the vaccine was
roduced to exercise its regulatory functions.
In 1996 the procedure was further developed [22] to allow for
hree signiﬁcant changes:
Increase in importance to Good Manufacturing Practices (GMP)
compliance. Previous versions of the procedure were more
focused on testing the quality rather than seeking built in quality.
Submission of a deﬁned summary ﬁle or dossier which would
provide documented information on the production process and
quality control as well as information supporting the claims of
both clinical safety and efﬁcacy of the vaccine.
Increase in the participation and role of the national regulatory
authority (NRA) of the manufacturing country.
Independent testing of ﬁnal vaccine lots by WHO  contracted
aboratories remained a requirement as a means to conﬁrm con-
istency of ﬁnal product characteristics. The site visit to the
anufacturing site became a more systematically deﬁned part of
he procedure.
Table 1 compares the different versions of the prequaliﬁca-
ion procedure and shows its main features. It shows the changes
ntroduced over time, from 1987 to date in order to strengthen it
nd to make it correspond more with emerging needs and with
urrent regulatory trends and expectations [10,21–25].
A milestone in the development of the prequaliﬁcation process
as the decision taken in 2000 to require the NRA in the producing
ountry to be functional as a prerequisite for acceptance of sub-
issions from manufacturers from that country. This change wasndorsed and stated in the 2002 version of the procedure. This sin-
le change to the procedure had the greatest impact on the WHO
fforts to strengthen capacity for vaccine regulation in developing
ountries.cine 33 (2015) 52–61 55
An important example of adjustments made to the procedure
to address emerging needs is implementation of a mechanism to
deﬁne and assess suitability of product characteristics for the target
immunization programmes. This is a key feature that distinguishes
PQ from a normal registration procedure or licensing mechanism
by the NRA of the producing country. While the NRA focuses its
review for registration on the speciﬁc needs of its own popula-
tion, the prequaliﬁcation emphasizes the review of data related to
efﬁcacy of the product in the target population, using the WHO
recommended immunization schedules (which may differ from
those recommended in the country of origin) and in co-
administration with other vaccines recommended in the NIPs
schedule. PQ also focuses on the programmatic suitability of the
product for the target user countries. For example, vaccines ﬁlled
in non-auto disable pre-ﬁlled syringes are not acceptable for pre-
qualiﬁcation due to the risk of re-use and unsafe disposal. The
Programmatic Suitability for Prequaliﬁcation (PSPQ) [26] describes
characteristics that are suitable and those that are unsuitable for
national immunization programmes in UN supplied countries. The
submission of a product deviating from a critical characteristic is
referred to a standing committee composed of programme experts
and regulators. They review relevant information and to make a rec-
ommendation to the WHO  PQ secretariat on whether the product
can proceed or not to prequaliﬁcation evaluation. The PQ process
also ensures that the UN tender speciﬁcations are met.
The PQ procedure includes different options (Table 2) aimed at
guiding the evaluation process in different situations, such as the
use of the fast track option for emergency situations, or streamlin-
ing the procedure in the case of vaccines which have followed the
EMA  Scientiﬁc Opinion regulatory pathway [27]. These provisions
are also aimed at accelerating the timeframe for prequaliﬁcation,
increasing efﬁciency, transparency and communication to stake-
holders, as well as the need to efﬁciently respond to increased
demand, and to assess novel.
Fifteen years ago, the programme had very limited funds, fully
provided by UNICEF by levying a small percentage on each pur-
chase order. In order to increase the capacity of the programme,
and expand its portfolio, an agreement was reached with UNICEF
and vaccine manufacturers to drop this percentage and to charge
a fee directly to manufacturers for the service that was provided.
Fees are revised at regular intervals to reﬂect increased costs. This
funding mechanism has supported the programme to the present
time. The programme is also sustained by ad hoc contributions
from donors (UNICEF, Bill and Melinda Gates Foundation, USAID
and some national governments such as the Netherlands), which
have been essential to increase stafﬁng and to support the post-
prequaliﬁcation monitoring activities.
Post-prequaliﬁcation activities (Table 3) enable the monitoring
of the performance of vaccines shipped to countries and for WHO  to
rapidly react in cases of non-compliance. This post-prequaliﬁcation
work is almost entirely supported through UNICEF funding and
contributions from PAHO and other Regional Ofﬁces.
The procedure used for the prequaliﬁcation of vaccines was used
as a basis for the formulation of the medicines prequaliﬁcation
procedure and later for selected diagnostics. However, a different
approach to prequaliﬁcation was followed by the medicines pro-
gramme. In this case, the functionality of the NRA is not required
for the acceptance of a generic product from any particular country,
if the manufacturer meets the deﬁned standards of quality, safety
and efﬁcacy. In the case of vaccines, this approach is not considered
feasible taking into account the complexity and inherent variability
of biological products thus requiring a partnership with the NRA to
provide lot-to-lot oversight. The different nature of the products
assessed and the different level of risk (e.g.: generic medicines vs.
biological products) are important scientiﬁc reasons for different
approaches between WHO  prequaliﬁcation programmes [28].
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Table 1
Evolution of the WHO  prequaliﬁcation procedure for vaccines: 1987–2010.
Characteristic 1987 1989 1997 2002 2005 2010
Pre-conditions for acceptance of submissions
None required but concept of reliance on NRA already present
Functionality of NRA as pre-requisite for submission
Requires MA in country of origin or EMEA Scientiﬁc Opinion (Art. 58)
WHO  recommendations or guidelines are available
Candidate vaccine present on list of priority products for
prequaliﬁcation
Candidate vaccine meets mandatory characteristics for Programmatic
Suitability for Prequaliﬁcation (PSPQ) (Ref)
Assessment procedure
Technical evaluation of quality,
safety and efﬁcacy
Copy of licensure by NRA in country of origin and other documents.
Requires submission of Product File containing limited information
Requires submission of Product Summary File (PSF) with deﬁned
format and contents (10 Chapters)
Acceptance of Common Technical Document (CTD) as alternative to
PSF
Strengthened requirements for demonstration of clinical efﬁcacy and
safety
Requires application letter in advance to actual submission of PSF
Pre-evaluation meetings between manufacturer and WHO-PQ and NRA
Screening of ﬁles for compliance in format and contents prior to
formal review
Increased focus on the suitability of product characteristics to the
target NIP
Compliance with PSPQ mandatory characteristics
Deviation from critical characteristic triggers referral to PSPQ standing
committee
Consistency Independent testing of samples, review of release certiﬁcates and SLP
Inspection/site visit/site audit Inspection: focus on production, quality control and records
Inspection: team of experts, one WHO  staff plus one representative
from NCL
Site visit: additional focus on Quality Assurance and GMP
Site visit: team of experts on each area, WHO  staff, representative of
NRA and UN agency representative may  elect to join
Written report sent to manufacturer. Improvements may  be required
before decision
Debrieﬁng sessions to manufacturer held on daily basis and on ﬁnal
day
Availability of reports of recent inspections conducted by NRAs may  be
used to streamline the audit by WHO
Ad hoc committee on PQ to advise on ﬁnal outcome of the evaluation
when needed
Consultation meeting with responsible NRA to discuss regulatory
status of the vaccine and to agree on future information sharing
(nature and mechanism)
Collaboration arrangements are signed with NRA for information
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In some instances the pressure on vaccine manufacturers to
ncrease capacity leads to introduction of changes in the manu-
acturing processes aimed at increasing yields, purity or achieving
ther improved characteristics. Scaling up manufacturing, reno-
ating or building up new facilities, new equipment and changes
n processes may  impact product characteristics, thus requiring
pproval by the NRA prior to the review by the PQ experts.
As for drugs, the procedure in place for the prequaliﬁcation
f diagnostics [29] does not require the functionality of the NRA.
he main reason for this is the fact that in many countries where
hese diagnostics are produced, the NRAs are not yet developed
nough to ensure their regulation. Similarly to the situation with
eneric medicines, the risk assessment analysis remains favourable
o enable WHO  prequaliﬁcation in absence of a recognized func-
ional NRA in the country of manufacture.In spite of different approaches among the PQ programmes,
specially with respect to the role played by the local NRA and
he funding mechanism, the three programmes have very simi-
ar approaches with respect to the way in which the evaluationof products is performed: a review of a dossier, consistency testing
of samples or performance evaluation and inspection/audit of the
manufacturing facilities.
6. Current challenges facing the vaccines prequaliﬁcation
programme
Vaccines are one of the most successful and cost-effective health
interventions. According to the State of the World’s Vaccines and
Immunization report (2009) “Immunization – even with the addi-
tion of the new, more costly vaccines – remains one of the most
cost-effective health interventions.” The publication remarks that
“more children than ever before are being reached with immuniza-
tion: over 100 million children per year in the period 2005–2007.
And the beneﬁts of immunization are increasingly being extended
to adolescents and adults – providing protection against life-
threatening diseases such as inﬂuenza, meningitis, and cancers that
occur in adulthood” [30].
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Table  2
Measures to strengthen the procedure: period 1987–2013.
Characteristic 1987 1989 1997 2002 2005 2010
Measures to improve the procedure
Cost of inspection/site visit/site audit paid by manufacturer
Inclusion of conﬁdentiality and non-conﬂict of interest clauses
Provision for evaluation of products formulated and ﬁlled by a manufacturer purchasing bulk
material from a prequaliﬁed source
Establishes criteria to consider waiving the site visit
Establishes a funding mechanism based on fees for service to the manufacturers
Validity of the prequaliﬁcation two years
Validity of prequaliﬁcation is between two and ﬁve years depending on performance
Prequaliﬁcation and reassessment scope and frequency based on risk analysis
Includes special considerations for fast-track procedure in emergency situation or case of acute
shortage of vaccine
Strict timelines for evaluation (target 12 months without counting time taken by manufacturer to
provide responses to questions or corrective actions)
Includes special considerations for accepting submissions before license is granted
Includes special considerations for accepting submissions of vaccines that have been licensed in
countries different from that of manufacturer
Introduces a streamlined procedure for evaluation of vaccines regulated by stringent regulatory
authorities and deﬁnes basis for selection of the authorities. Evaluation process based on review
of  reports provided by the NRA
Introduces a streamlined procedure for evaluation of vaccines which were granted a positive
Scientiﬁc Opinion by the CHMP (Art. 58)
Special considerations for vaccines produced in multiple sites or different countries
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PImproved communication and transparency through upgraded web  list and other
documents (rationale for PQ, statements on investigation of AEFIs and complain
consider for manufacturers)
According to data presented in the Global Vaccine Action Plan
31], the annual number of deaths among children under ﬁve years
f age fell from an estimated 9.6 million in 2000 to 7.6 million in
010, despite an increase in the number of children born each year.
his is the result of improved access to clean water and sanitation,
ncreased immunization coverage and the integrated delivery of
ssential health interventions.
Despite this progress, vaccine-preventable diseases remain a
ajor cause of morbidity and mortality. Adoption of new vaccines
y low- and middle-income countries has been slower than in high-
ncome countries. In 2010, for example, only 13% of the total high
ncome country birth cohort lived in countries that did not have
neumococcal conjugate vaccines in their immunization sched-
les. Of the total low-income country birth cohort, 98% lived in
ountries that did not have pneumococcal conjugate vaccines in
heir schedules [31].
In January 2000, the Global Alliance for Vaccines and Immu-
ization (GAVI) was launched with the aim to fund vaccines
or children in the world’s 70 poorest countries. Its mission is
o save children’s lives and protect people’s health by increas-
ng access to immunization in the world’s poorest countries. By
ulling together the expertise and support of global key players in
able 3
ost-prequaliﬁcation activities to monitor performance of the prequaliﬁed vaccines: peri
Characteristic 
Post-prequaliﬁcation activities
All lots released by NRA, release certiﬁcates to be provided upon request
Retention samples for testing by WHO  contracted laboratories upon request
Reporting of changes (variations)
Reporting of changes (variations) with guidance on what and when to report
Reassessments based on site visit and testing if needed
Reassessment based on fully updated PSF, testing and site visit
Provides criteria to deﬁne frequency and scope of reassessment requirements. Site
visit can be waived if criteria are met, but at least one every ﬁve years
Frequency and scope of reassessments based on risk analysis
Random testing to monitor continued compliance with speciﬁcations
Introduces requirement for Prequaliﬁed Vaccines Annual Reports (PQVARs)
Monitoring and investigation of complaints and reports of AEFI
Recommendations for action in case of non-complianceished
ints to
immunization – WHO, UNICEF, the World Bank, the Bill & Melinda
Gates Foundation, donor governments, developing countries,
international development and ﬁnance organizations and the
pharmaceutical industry, the access to vaccines in national immu-
nization programmes in developing countries has increased in
recent years bridging the gap in immunization coverage for basic
vaccines, accelerating the introduction of novel vaccines and fos-
tering research and development of vaccines targeted to diseases
endemic in developing countries [32].
The GAVI focuses its efforts on low and lower middle income
countries and prioritizes a number of vaccines for introduction.
Their current portfolio of priority vaccines includes the follow-
ing: human papilloma virus (HPV), measles rubella, measles second
dose, meningococcal A conjugate (Men A), pentavalent (diphtheria-
tetanus-pertussis, hepatitis B, Haemophilus inﬂuenzae type b),
pneumococcal conjugate, rotavirus, and yellow fever [32].
GAVI prioritized vaccines that are supplied to eligible countries
through the UN centralized procurement mechanisms require pre-
qualiﬁcation as a condition for purchase.Acceleration or increase of vaccine access leads to an increased
demand for prequaliﬁcation both by requiring expansion of
the portfolio (types of vaccines assessed) as well as securing
od 1997–2013.
1987 1989 1997 2002 2005 2010
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Table 4
Sources of prequaliﬁed vaccines.
Year No. of vaccine types Number of suppliers % from emerging
economies
1986 6 13 13
1996 13 18 37
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Table 5
Evolution of post-prequaliﬁcation, and other PQ, activities.
Post PA and other PQ activities 2009 2010 2011 2012
Reassessments 11 12 10 12
Annual reviews 6 21 74 53 (448)
Testing 124 159 183 105
Complaints/other issues of concern 3 13 16 15
AEFIs 7 7 7 14
limited number of laboratories, and in some cases is restricted to2006 24 22 55
2012 33 27 48
nough supply sources for each vaccine used in immunization
rogrammes.
With the availability of licensed vaccines used to prevent and
ontrol 25 vaccine preventable diseases, it is now time to show
ommitment to achieve the full potential of immunization. The
ollective recognition of this opportunity has led the global health
ommunity to call for a Decade of Vaccines, in line with the requests
ade in resolution WHA  61.15 on the global immunization strat-
gy. “The vision for the Decade of Vaccines (2011–2020) is of a
orld in which all individuals and communities enjoy lives free
rom vaccine-preventable diseases. The mission of the Decade of
accines is to extend, by 2020 and beyond, the full beneﬁt of immu-
ization to all people, regardless of where they are born, who  they
re or where they live.
The Global Vaccine Action Plan reiterates existing goals and sets
ew goals for the decade, proposes six strategic objectives and the
ctions that will support their achievement” [31].
Increasing number of vaccines are being produced in develop-
ng countries due to mergers, acquisitions, outsourcing of vaccine
roduction steps including ﬁlling, freeze drying and labelling
33,34]. In this context, the prequaliﬁcation programme addresses
n extensive portfolio of vaccines [35] of variable complexity, some
f them produced in multiple sites in single or different countries.
ork towards expanding the supply base to secure availability of
raditional, under used and recently introduced vaccines for global
upply entails exploring potential suppliers from countries with
ecently declared functional NRAs. These candidate manufactur-
rs usually do not have experience with exporting vaccines and
re therefore not familiar with the international standards of qual-
ty required by the WHO  prequaliﬁcation programme. The NRAs of
he countries where these vaccines are manufactured are also new
o the required standards and regulatory expectations; sustainable
requaliﬁcation represents thus a challenge for them as well as for
HO.
Table 4 updates previous published information [20] and show
 steady increase in the types of vaccines included in the prequal-
ﬁcation portfolio and the number of suppliers. The percentage
f suppliers from emerging economies showed rapid increase
ntil 2006 and has now diminished relative to the total, most
ikely due to the prequaliﬁcation of a signiﬁcant number of novel
accines developed and initially produced by developed country
anufacturers. Suppliers have been categorized as from emerg-
ng economies when their products are regulated by NRAs from
ountries in this category.
Another current challenge is sustainability of supply which is
ritical to vaccine security for national immunization programmes.
n this respect, the role of the prequaliﬁcation programme is even
ore important in the post-prequaliﬁcation phase than before pre-
ualiﬁcation is granted. The continuing monitoring of quality and
erformance of prequaliﬁed vaccines in use in the target countries
s an important component of the activities of the programme. This
mplies testing of vaccine lots shipped to countries to ensure that
he vaccines continue to meet the established speciﬁcations (both
HO recommended and UN tender-related), review and approval
f variations introduced to the manufacturing process or quality
ontrol methods, monitoring and investigation of reports of adverseMeetings with manufacturers 62 80 71 119
Meetings with NRAs/other stakeholders 33 86 64 109
reactions and of complaints. Table 5 shows the increase in post-
prequaliﬁcation related activities between 2009 and 2012.
Changes to the prequaliﬁcation procedure introduced in the
last revision adopted by ECBS in 2010 and implemented since
February 2012 [25] aim at addressing these challenges: decreasing
time taken for prequaliﬁcation; improving assistance provided in
response to complaints from the ﬁeld and reports of AEFIs; and
improving transparency and communication to stakeholders and
public as well as maximizing the efﬁcient use of resources. Par-
ticularly relevant is the introduction of a streamlined procedure
for the evaluation of vaccines produced in selected countries with
NRAs that are considered stringent (Australia, Belgium, Canada,
EMA, France, Italy and USA), and that agree to collaborate with
WHO by providing the assessment reports, inspection reports, and
test results for the candidate products. These authorities are also
engaged in establishing continuing communication with the PQ
programme in case problems are identiﬁed in the quality, safety
or efﬁcacy of the prequaliﬁed vaccines under their jurisdictions.
It is expected that increased reliance in the work performed by
these NRAs will free capacity at the PQ secretariat to focus increased
attention on vaccines that have been recently licensed and pre-
qualiﬁed and are produced by less experienced manufacturers in
countries with less robust NRAs. Usually, such products require a
closer monitoring due to need for scaling up production, improve-
ment of product characteristics and other needs that may entail
signiﬁcant changes in the production process or QC methods used.
7. Performance of the vaccines prequaliﬁcation
programme
The stafﬁng of the programme in 2013 consists of one pro-
gramme  manager, six professionals and four support staff. Four
of these professionals are quality experts (focused on performing
quality reviews), one is a clinical expert (for clinical reviews) and
one is a testing expert (sample testing). Three secretaries provide
all the administrative support; two  are trained in and responsible
for the logistics of receiving, keeping and shipping vaccine samples
for independent testing in the WHO  contracted laboratories.
This small secretariat works in close collaboration with, and
with the contribution of, NRAs worldwide, eight from industrial-
ized countries and seven from emerging economies. These NRAs
donate staff time to contribute to the programme in the quality
evaluation of the candidate vaccines. However, for the evaluation of
the clinical data a network of independent clinical experts is used.
The evaluation of manufacturers in terms of GMP  is secured by
contracting independent experts, although some NRAs also make
in kind contributions of national experts.
A network of 12 laboratories worldwide secures the testing
needs of the programme [36]. Independent testing of vaccine sam-
ples remains a challenge, particularly for novel vaccines where
the expertise to perform the required tests rests with a verythe National Control Laboratory (NCL) of the producing country.
Securing a minimum level of expertise worldwide to perform rel-
evant tests independently from the manufacturers remains one
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f the objectives of the prequaliﬁcation programme. Work with
anufacturers has been initiated to foster establishment, through
ethodology transfer to at least one laboratory in addition to the
CL responsible for lot release. Additional work has been initiated
ith view at harmonizing test methodologies between the differ-
nt WHO  contracted laboratories in cases where this is relevant.
As part of the assessment of the performance of the prequaliﬁca-
ion process, in April 2012 the PQ Programme commissioned a sur-
ey with a specialized company addressed to vaccine manufactur-
rs to measure the quality of service provided by the programme.
The objectives of the survey were to look at the quality of service
esign (process) and service delivery (people) particularly in the
ontext of ﬁle review and site audits, with a view to identifying
reas for improvement. The survey participants included manufac-
urers with one or more prequaliﬁed vaccines.
A list of 81 potential contacts was developed with intervention
f regulatory affairs professionals (for the ﬁle review aspects) and
f quality assurance professionals (for the site audit aspects). There
as a 54% response rate with 23 of 29 companies providing com-
leted response to the survey. PQ service was measured on a 7 point
cale (SERVQUAL) [37] with two additional questions to describe
he expectations from manufacturers: minimum level of service
minimum level of service performance acceptable to the manu-
acturer from any major regulatory agency) and desired level of
ervice (the level of service performance that a regulatory agency
hould deliver). These two additional measures provide a range of
cceptable level of service quality.
The main ﬁndings of the survey were the following:
Vaccine manufacturers consider that the service provided by the
WHO  vaccines prequaliﬁcation programme is within the range
of an acceptable level of performance compared to agencies that
review and approve vaccine products.
In no area in the study is the PQ programme performing signiﬁ-
cantly below manufacturers’ minimum expectations.
Overall, the programme is especially strong in those aspects of
service that build applicant’s conﬁdence and increase their com-
fort level with the overall process.
Major strengths identiﬁed were the following:
Providing the same reviewers throughout the ﬁle evaluation
Clarity of questions asked during the site audits
Auditors who handle conﬁdential data/information in a way that
makes applicants feel safe
Providing direct access to team leader to address technical ques-
tions or deﬁciencies
Providing timely announcement of audits
Agency rationale for the list of priority vaccines
Major areas for improvement identiﬁed by manufacturers were
he following:
Concern about overall time required for prequaliﬁcation and pro-
cess time inefﬁciencies (overall elapsed time, knowing when to
expect a response).
Sample testing is an area in which the programme is performing
at minimum level of expectations.Suggestions from the manufacturers for process improvement
ere the following:
Implementing ﬁxed timelines for review and response.cine 33 (2015) 52–61 59
• More up-front collaboration between applicants and the WHO-
PQ to develop a shared understanding of requirements and
deliverables.
• Sample testing performed in parallel with the Product Summary
File (PSF) review.
Suggestions from the manufacturers for delivery improvement
were the following:
• Improved communications and follow up.
• Timely feedback/reporting.
• Consistency in GMP  interpretation.
Some of these areas for improvement have been addressed
through changes introduced in the procedure in the 2010 version
[25] by implementation of a streamlined procedure for products
originating in countries with experienced NRA/NCLs, by waiving
the requirement for testing in cases where the NCL in those pro-
ducing countries have conﬁrmed production consistency through
independent testing and agrees to share their results with WHO,
by tightening the monitoring of timelines taken to complete the
different steps of the procedure (through an internal monitoring
tool), by encouraging meetings between manufacturers and WHO-
PQ secretariat in advance to submissions and during evaluation to
improve communication and to develop a shared understanding of
requirements and deliverables. Furthermore, the secretariat pub-
lishes points to consider type documents to provide clear guidance
to manufacturers on PQ expectations in different areas or aspects
of the process [38–40]. Three additional documents are currently
under development. These are addressing important and current
issues: variations, validation of manufacturing process and risk
analysis in case of deviations [unpublished].
In spite of the efforts to improve the performance of the pro-
gramme  to meet manufacturers and country expectations, a few
constraints remain to be addressed. The most important one has to
do with the lack of capacity at global level for testing novel vaccines.
This lack of capacity is important not only at the time of evaluation
of candidate vaccines but even more during the introduction phase
of such vaccines into immunization programmes. The aspiration of
manufacturers of having their vaccines tested in parallel with the
ﬁle review is difﬁcult to realize unless methodology transfer to the
relevant and other NCLs is ensured in advance to registration and
prequaliﬁcation submissions, which is not always achieved.
Another area highlighted by manufacturers as requiring some
improvement was  related to consistency in interpretation of GMP
requirements. An ongoing review of the GMP audits performed by
the team will allow implementing a corrective action plan aimed
at achieving a greater alignment in the way  GMP  requirements are
enforced.
8. Looking into the future
The programme perceives itself as an interim mechanism
required to secure vaccines of assured quality for countries while
appropriate procurement expertise and regulatory capacity for vac-
cines is developed. Ideally, regulatory capacity will increase over
time up to a point where the programme will become irrelevant.
At least three fundamental conditions are required to make of
this goal a reality: strong regulatory capacity in all exporting
countries; sufﬁcient regulatory capacity in the receiving countries;
and decentralized procurement mechanisms (direct procurement
by countries or groups of countries).
Currently, of the 90–100 countries served by UNICEF, the major-
ity have limited or no regulatory expertise for vaccines. The
situation is different in countries served by the PAHO Revolving
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und, where several have been satisfactorily evaluated with respect
o their regulatory capacity. In any case, devolving the responsibil-
ty of assuring the quality of imported vaccines to each and every
RA from low and middle income user countries is an unrealistic
hort or mid-term expectation in most regions of the world.
The WHO  Region of the Americas (PAHO/AMRO) is perhaps the
xception to the rule, since several countries of the Region have well
eveloped regulatory capacity. Since PAHO acts also as an impor-
ant UN purchasing agency through its Revolving Fund [41], this
egion could consider accepting for purchase products that have
een registered by a functional authority in the region and which
re commercialized in the country that has granted the marketing
uthorization. However, such an approach has several challenges to
eplicate the service that is currently offered by the prequaliﬁcation
rogramme. For example:
1) There would be no guarantee that a single standard of quality,
safety and efﬁcacy is applied, i.e. WHO  recommended require-
ments for vaccines.
2) The clinical data reviewed may  be applicable to the popula-
tion of the country granting the registration but not necessarily
elsewhere.
3) Review of data related to immunization schedules and co-
administration with other vaccines may  also be restricted to
the policies in use in the country granting the registration.
4) Vaccine presentation issues may  not have been considered
5) Finally a very important constraint of such approach would be
the lack of a mechanism to deal with the post-marketing activ-
ities, including management of complaints, reports of AEFIs,
monitoring of continued compliance, approval of variations,
etc.
An alternative option, potentially more widely applicable, could
e to make use of pooled expertise based on a collective effort. Sev-
ral WHO  regions have established networks of regulators aimed
t information sharing, strengthening regulatory capacity, harmo-
ization of standards and procedures and ultimately as a long term
oal achieving mutual recognition of work done by others in the
etwork. There are also regulatory networks established as part
f trade agreements between countries. Use of networks can be
nvisaged as a way to pool expertise to assess vaccines that are
riority for a speciﬁc region. This approach has the advantage
f leveraging expertise from different countries, wherever this is
tronger, agreement on a common standard to be applied, sharing
esources between the participating countries and establishing a
ollaborative and consensual mechanism for decision making. This
pproach may  allow focusing on the speciﬁc needs of NIPs in the
egion in terms of clinical data, immunization schedules and pro-
rammatic characteristics. The network could and should monitor
nd investigate complaints and Adverse Events Following Immu-
ization at least within their territory.
The EMA  represents an example of a well-functioning regulatory
etwork.
Decision making by the network regulators may  well be valid for
rocurement of vaccines within the region but may  not be automat-
cally extrapolated or acceptable to other regions.
An important aspect to consider in any scheme alternative to the
urrent PQ is the procurement mechanism. If the vaccine supply to
ow, low middle income and middle income countries continues
o be managed through centralized procurement, diversiﬁcation
f decision making, of standards used, and decentralized manage-
ent of complaints and AEFI may  be difﬁcult to deal with and notuitable for the procurement agencies. In addition, such diversiﬁ-
ation would also impact and increase workload for manufacturers
ho would have to deal with several independent authorities and
heir individual requirements.cine 33 (2015) 52–61
Currently, there are a few regional procurement mechanisms in
place that are independent from UN, i.e. for Gulf countries [42]. A
regional regulatory network associated to a regional procurement
mechanism may  work for a particular region.
A complete elimination of global PQ functions would neces-
sarily require to be linked to a decentralization of procurement
to regional level with reliance on a regional regulatory network
decision making body. This will require increased regional pro-
curement expertise. This approach carries the risk of creating a
fragmented market, increased prices unless a low cost supply is
locally available, higher transaction costs, loss of global suppliers.
Market fragmentation might negatively impact on product innova-
tion and supply.
If a future replacement mechanism, whatever it is, is not fully
accepted by user countries, it could end in a shift to products man-
ufactured in countries with stringent NRAs, or conversely only
from emerging manufacturers, leading to a potential loss of market
diversity and potentially also price implications.
With the current procurement mechanism being centralized, it
is the view of the authors that a network approach would be the
most feasible approach provided that a minimum of functions is
maintained at WHO  level as a centralizing body partnering with
both the evaluating network and the procurement agencies. The
role of WHO  would be to ensure suitability of clinical data and prod-
uct characteristics at global level and more importantly to address
in a consolidated manner the post-marketing functions.
Continuing work is required from WHO  and partners to further
strengthen regulatory capacity and expertise globally, and there is
a need to test any alternative approach to PQ in at least one region
to assess its feasibility. Proper transitioning of functions from PQ to
national regulators would require the development of a road map
with clear milestones and expected timeframes for implementa-
tion.
9. Conclusions
The WHO  prequaliﬁcation programme for vaccines has con-
tinually developed and evolved over a 25 year-period. Currently
127 vaccines are prequaliﬁed. These are used in 134 countries and
approximately 64% of the global birth cohort is immunized with
prequaliﬁed vaccines. The prequaliﬁcation “seal of approval” is a
powerful driver not only of public health but also of industrial policy
development in countries that wish to supply international mar-
kets. Reliance of the NRA of record in the manufacturing country has
also provided a powerful incentive to develop regulatory capacity.
The prequaliﬁcation service provided by WHO  is however consid-
ered to be an interim solution as national capacity for procurement
and regulatory processes is built. As the programme enters the next
period of its evolution, plans are being developed and articulated
for an eventual phased transition to increased country responsi-
bility, perhaps through a collaborative effort between Regulatory
Networks and WHO.
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